SCHEMBL7542404

SCHEMBL7542404

CC(C(=O)O)c1ccc(C2CCCC2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 15/20 0.60
PTGS2 P35354 15/20 0.60
OPRK1 P41145 1/20 0.60
HTT P42858 1/20 0.60
KMT2A Q03164 1/20 0.60
MT-CO1 P00395 1/20 0.46
MT-CO2 P00403 1/20 0.46
APP P05067 1/20 0.42
LMNA P02545 2/20 0.41
CYP2C9 P11712 2/20 0.41
AKR1C3 P42330 2/20 0.41
CXCR1 P25024 2/20 0.41
CXCR2 P25025 2/20 0.41
ALB P02768 1/20 0.41
ESR1 P03372 1/20 0.41
ALOX5 P09917 1/20 0.41
RARB P10826 1/20 0.41
ADRB3 P13945 1/20 0.41
NFKB1 P19838 1/20 0.41
HTR2A P28223 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124237 0.78 HPGD (0.42) PTGS1PTGS2OPRK1HTTKMT2A
SCHEMBL9643202 0.77 PTGS1 (0.51) PTGS1PTGS2OPRK1HTTKMT2A
SCHEMBL11468007 0.76 APP (0.64) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL11133884 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL28914092 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL24423 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL28562193 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL28562194 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL28914090 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A
Loxoprofen SCHEMBL14312087 0.75 PTGS1 (1.00) PTGS1PTGS2OPRK1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1625411-A Combination of a NSAID and a PDE-4 inhibitor ALTANA PHARMA AG (DE) 2005-06-08 CN claimed
CN-119241545-A Matrine tricyclic derivative and application thereof in preparation of medicines for treating hepatic fibrosis 中国人民解放军海军军医大学 2025-01-03 CN disclosed
US-20210078941-A1 Method For Preparing Substituted Phenylacetic Acid Derivative JIANGSU RUIKE MEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2021-03-18 US disclosed
EP-3680227-A1 METHOD FOR PREPARING SUBSTITUTED PHENYLACETIC ACID DERIVATIVE Jiangsu Ruike Medical Science And Technology Co., Ltd. (CN) 2020-07-15 EP disclosed
CN-1278672-C Pharmaceutical composition for intramuscular injection containing loxoprofen SHIN POONG PHARMACEUTICAL CO (KR) 2006-10-11 CN disclosed
CN-1400892-A Pharmaceutical composition for intramuscular injection containing loxoprofen SHIN POONG PHARMACEUTICAL CO (KR) 2003-03-05 CN disclosed
WO-2002047661-A1 PHARMACEUTICAL COMPOSITION FOR INTRAMUSCULAR INJECTION CONTAINING LOXOPROFEN SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078941-A1 Method For Preparing Substituted Phenylacetic Acid Derivative ALOX5, LOXL4, CYP3A5 PTGS1 654/4885PTGS2 731/4885OPRK1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.